Factor VIII replacement is still the standard of care in haemophilia A

被引：95
作者：
Aledort, Louis [1 ]
Mannucci, Pier Mannuccio [2 ]
Schramm, Wolfgang [3 ]
Tarantino, Michael [4 ,5 ]
机构：
[1] Icahn Sch Med Mt Sinai, Div Hematol Oncol, New York, NY 10029 USA
[2] IRCCS Fdn Ca Granda Maggiore Policlin Hosp, Sci Direct, Via Pace 9, I-20122 Milan, Italy
[3] Univ Hosp Munich, Dept Transfus Med & Haemostasis, Munich, Germany
[4] Univ Illinois, Coll Med, Peoria, IL 61656 USA
[5] Bleeding & Clotting Disorders Inst, Peoria, IL USA
来源：
BLOOD TRANSFUSION | 2019年 / 17卷 / 06期
关键词：
factor VIII; haemophilia A; prophylaxis; standard of care; half-life; RECOMBINANT FACTOR-VIII; FC FUSION PROTEIN; EXTENDED-HALF-LIFE; BAY; 94-9027; EMICIZUMAB PROPHYLAXIS; BISPECIFIC ANTIBODY; IMMUNE TOLERANCE; FULL-LENGTH; ON-DEMAND; SAFETY;
D O I：
10.2450/2019.0211-19
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Prophylactic factor VIII (FVIII) has dramatically improved haemophilia A treatment, preventing joint bleeding and halting the deterioration of joint status. FVIII products with an extended plasma half-life further improve patients' quality of life and increase therapeutic adherence. New licensed classes of non-replacement products include prophylactic emicizumab, which is administered subcutaneously up to every 4 weeks. However, this drug is not suitable for acute bleeding episodes or management of major surgery, and long-term data on the impact of emicizumab on joint health, FVIII inhibitor development and thrombotic risk are awaited. Prophylaxis with FVIII replacement remains the standard of care in haemophilia A, with the aim of achieving a level of haemostasis control that allows patients to meet their lifestyle goals.
引用
收藏
页码：479 / 486
页数：8
相关论文
共 69 条
  • [21] Perioperative haemostasis with full-length, PEGylated, recombinant factor VIII with extended half-life (rurioctocog alfa pegol) in patients with haemophilia A: Final results of a multicentre, single-arm phase III trial
    Gruppo, Ralph
    Lopez-Fernandez, Maria-Fernanda
    Wynn, Tung T.
    Engl, Werner
    Sharkhawy, Marlies
    Tangada, Srilatha
    [J]. HAEMOPHILIA, 2019, 25 (05) : 773 - 781
  • [22] First report on the safety and efficacy of an extended half-life glycoPEGylated recombinant FVIII for major surgery in severe haemophilia A
    Hampton, K.
    Chowdary, P.
    Dunkley, S.
    Ehrenforth, S.
    Jacobsen, L.
    Neff, A.
    Santagostino, E.
    Sathar, J.
    Takedani, H.
    Takemoto, C. M.
    Negrier, C.
    [J]. HAEMOPHILIA, 2017, 23 (05) : 689 - 696
  • [23] The principal results of the International Immune Tolerance Study: a randomized dose comparison
    Hay, Charles R. M.
    DiMichele, Donna M.
    [J]. BLOOD, 2012, 119 (06) : 1335 - 1344
  • [24] Hoots WK, 2007, EMERGENCY CARE ISSUE, V43
  • [25] Using pharmacokinetics to individualize hemophilia therapy
    Iorio, Alfonso
    [J]. HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2017, : 595 - 604
  • [26] PEGylated therapeutic proteins for haemophilia treatment: a review for haemophilia caregivers
    Ivens, I. A.
    Baumann, A.
    McDonald, T. A.
    Humphries, T. J.
    Michaels, L. A.
    Mathew, P.
    [J]. HAEMOPHILIA, 2013, 19 (01) : 11 - 20
  • [27] JIMENEZYUSTE V, 2017, BLOOD S1, V130
  • [28] A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model
    Kitazawa, Takehisa
    Igawa, Tomoyuki
    Sampei, Zenjiro
    Muto, Atsushi
    Kojima, Tetsuo
    Soeda, Tetsuhiro
    Yoshihashi, Kazutaka
    Okuyama-Nishida, Yukiko
    Saito, Hiroyuki
    Tsunoda, Hiroyuki
    Suzuki, Tsukasa
    Adachi, Hideki
    Miyazaki, Taro
    Ishii, Shinya
    Kamata-Sakurai, Mika
    Iida, Takeo
    Harada, Aya
    Esaki, Keiko
    Funaki, Miho
    Moriyama, Chifumi
    Tanaka, Eriko
    Kikuchi, Yasufumi
    Wakabayashi, Tetsuya
    Wada, Manabu
    Goto, Masaaki
    Toyoda, Takeshi
    Ueyama, Atsunori
    Suzuki, Sachiyo
    Haraya, Kenta
    Tachibana, Tatsuhiko
    Kawabe, Yoshiki
    Shima, Midori
    Yoshioka, Akira
    Hattori, Kunihiro
    [J]. NATURE MEDICINE, 2012, 18 (10) : 1570 - U177
  • [29] Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A
    Konkle, Barbara A.
    Stasyshyn, Oleksandra
    Chowdary, Pratima
    Bevan, David H.
    Mant, Tim
    Shima, Midori
    Engl, Werner
    Dyck-Jones, Jacqueline
    Fuerlinger, Monika
    Patrone, Lisa
    Ewenstein, Bruce
    Abbuehl, Brigitt
    [J]. BLOOD, 2015, 126 (09) : 1078 - 1085
  • [30] Evaluating the safety of emicizumab in patients with hemophilia A
    Langer, Arielle L.
    Etra, Aaron
    Aledort, Louis
    [J]. EXPERT OPINION ON DRUG SAFETY, 2018, 17 (12) : 1233 - 1237
1234567